MetaCap

Bicycle Therapeutics (BCYC) vs Cypherpunk Technologies (CYPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cypherpunk Technologies (CYPH) has outperformed Bicycle Therapeutics (BCYC) over the past year, losing 38.2% versus a loss of 54.1%. Over five years, CYPH leads with a -94.4% price change compared with -94.7% for BCYC. Cypherpunk Technologies is the larger company by market cap ($210.1 million vs $203.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCYC-54.11%CYPH-38.16%
+89%+2%-85%
Nov 21, 20251 yearNov 20, 2026
BCYC-95.01%CYPH-93.79%
+50%-28%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCYC versus CYPH key metrics
MetricBCYCCYPH
Share price$2.90$1.41
Market cap$203.27M$210.15M
1-day change-4.92%-18.02%
YTD return-59.04%+21.55%
1-year return-54.11%-38.16%
5-year return-94.69%-94.45%
P/E ratio (TTM)—0.67
EPS (TTM)$-2.03$2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$72.59M—
Revenue growth (YoY)+105.77%—
Net income (latest FY)$-218.96M$4.82M
Operating margin-340.38%—
Net margin-301.66%—
52-week high$7.83$4.19
52-week low$2.85$0.491
Distance from 52-week high-62.96%-66.35%
Analyst consensusbuystrong_buy
Avg. price target upside+216.21%+254.61%
Average volume444.72K15.42M
Shares outstanding50.66M149.04M
Employees2886
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CYPH has outperformed BCYC by 16.0 percentage points over the past year.

About Bicycle Therapeutics

BCYC stock →

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing.

Health Care · Biotechnology: Pharmaceutical Preparations · 288 employees

About Cypherpunk Technologies

CYPH stock →

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

BCYC vs CYPH FAQ

Which is bigger, Bicycle Therapeutics or Cypherpunk Technologies?

Cypherpunk Technologies (CYPH) is larger, with a market capitalization of $210.15M compared with $203.27M for Bicycle Therapeutics (BCYC).

Which stock has performed better over the past year, BCYC or CYPH?

CYPH returned -38.16% over the past 12 months, compared with -54.11% for BCYC (price return, excluding dividends). Past performance does not predict future results.

Are Bicycle Therapeutics and Cypherpunk Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons